Since 2013, the company has added nearly 100 device development professionals to its staff at the DDC, and earlier this year it expanded its pilot manufacturing development Class 7 and 8 cleanroom space for drug-delivery and medical devices.
The expansion is the direct result of "new wins in the biologic/pharma drug-delivery, combination products and medtech spaces," says the company. Those wins include products with complex mechatronic assemblies and micro-manufacturing requirements, both of which support the global trend toward smaller and smarter devices. The company's global design and development organization has grown accordingly during this time frame, as its services have gained greater acceptance by the customer base, according to the contract manufacturer.
Phillips-Medisize envisages further expansions or acquisitions at its existing Europe and China locations, driven by global customers seeking local development and manufacturing services.
In June, Phillips-Medisize President and CEO Matt Jennings discussed the company's global business strategy and explained in some detail how the contract manufacturing landscape is shifting during a press conference at the MD&M East exposition and conference. For more on this, read "Why some manufacturers aren't bemoaning the skills gap."
